CN1083431C - 新的杂环化合物 - Google Patents

新的杂环化合物 Download PDF

Info

Publication number
CN1083431C
CN1083431C CN95191845A CN95191845A CN1083431C CN 1083431 C CN1083431 C CN 1083431C CN 95191845 A CN95191845 A CN 95191845A CN 95191845 A CN95191845 A CN 95191845A CN 1083431 C CN1083431 C CN 1083431C
Authority
CN
China
Prior art keywords
dibenzo
carboxylic acid
propyl group
dihydro
piperidine carboxylic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN95191845A
Other languages
English (en)
Chinese (zh)
Other versions
CN1142226A (zh
Inventor
K·E·安德逊
U·B·奥尔森
H·彼得逊
F·C·格龙瓦尔德
U·索尼瓦尔德
T·K·约根森
H·S·安德逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN1142226A publication Critical patent/CN1142226A/zh
Application granted granted Critical
Publication of CN1083431C publication Critical patent/CN1083431C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
CN95191845A 1994-01-04 1995-01-03 新的杂环化合物 Expired - Fee Related CN1083431C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK1994 1994-01-04
DK0019/94 1994-01-04
DK129094 1994-11-09
DK1290/94 1994-11-09

Publications (2)

Publication Number Publication Date
CN1142226A CN1142226A (zh) 1997-02-05
CN1083431C true CN1083431C (zh) 2002-04-24

Family

ID=26063135

Family Applications (1)

Application Number Title Priority Date Filing Date
CN95191845A Expired - Fee Related CN1083431C (zh) 1994-01-04 1995-01-03 新的杂环化合物

Country Status (31)

Country Link
US (8) US5595989A (https=)
EP (1) EP0738262B1 (https=)
JP (1) JP2944221B2 (https=)
KR (1) KR100329450B1 (https=)
CN (1) CN1083431C (https=)
AT (1) ATE191909T1 (https=)
AU (1) AU691858B2 (https=)
BG (1) BG100692A (https=)
BR (1) BR9506452A (https=)
CA (1) CA2180238A1 (https=)
CZ (1) CZ286109B6 (https=)
DE (1) DE69516394T2 (https=)
DK (1) DK0738262T3 (https=)
ES (1) ES2147837T3 (https=)
FI (1) FI114025B (https=)
GR (1) GR3033967T3 (https=)
HU (1) HUT75878A (https=)
IL (1) IL112222A (https=)
MY (1) MY113463A (https=)
NO (1) NO306295B1 (https=)
NZ (1) NZ277763A (https=)
PE (1) PE45095A1 (https=)
PL (1) PL180209B1 (https=)
PT (1) PT738262E (https=)
RU (1) RU2167152C2 (https=)
SG (1) SG50602A1 (https=)
SI (1) SI9520023A (https=)
SK (1) SK88196A3 (https=)
TW (1) TW300887B (https=)
UA (1) UA47396C2 (https=)
WO (1) WO1995018793A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY113463A (en) * 1994-01-04 2002-03-30 Novo Nordisk As Novel heterocyclic compounds
US6110913A (en) * 1994-01-04 2000-08-29 Novo Nordisk A/S N-substituted azaheterocyclic carboxylic acids and esters thereof
US6239148B1 (en) * 1994-01-04 2001-05-29 Novo Nordisk A/S N-substituted azaheterocyclic carboxylic acids and esters thereof
US5962449A (en) 1995-04-07 1999-10-05 Novo Nordisk A/S Tricyclic compounds in treating hyperalgesic conditions and NIDDM
US5716949A (en) * 1995-04-07 1998-02-10 Novo Nordisk A/S Heterocyclic compounds
UA54385C2 (uk) * 1995-04-07 2003-03-17 Ново Нордіск А/С N-заміщені азагетероциклічні карбонові кислоти та їх ефіри, спосіб їх одержання, фармацевтична композиція та спосіб лікування
US5698551A (en) * 1995-04-07 1997-12-16 Novo Nordisk A/S Heterocyclic compounds
US5952352A (en) * 1995-04-07 1999-09-14 Novo Nordisk A/S Heterocyclic compounds
JP3048067B2 (ja) * 1995-12-15 2000-06-05 ノボ ノルディスク アクティーゼルスカブ 新規方法
US6323206B1 (en) 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
CA2267500A1 (en) 1996-10-04 1998-04-16 Novo Nordisk A/S N-substituted azaheterocyclic compounds
ZA978792B (en) * 1996-10-04 1998-04-06 Novo Nordisk As N-substituted azaheterocyclic compounds.
WO1998015548A1 (en) * 1996-10-04 1998-04-16 Novo Nordisk A/S 1,4-disubstituted piperazines
US6040318A (en) * 1997-06-25 2000-03-21 Novo Nordisk A/S Tricycle substituted with azaheterocyclic carboxylic acids
AU749505B2 (en) 1997-10-27 2002-06-27 Dr. Reddy's Laboratories Limited Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
BR9910144A (pt) 1998-01-21 2002-04-02 Millennium Pharm Inc Antagonistas de receptores de quimiocinas e seu uso
US6433165B1 (en) * 1998-01-21 2002-08-13 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6509346B2 (en) 1998-01-21 2003-01-21 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6613905B1 (en) 1998-01-21 2003-09-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
ES2137136B1 (es) * 1998-05-18 2000-07-01 Esteve Labor Dr Empleo de derivados de aril (o heteroaril) azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de la inflamacion neurogenica.
US7271176B2 (en) * 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
US6468996B1 (en) * 1998-10-21 2002-10-22 Novo Nordisk A/S Substituted hetero-polycyclic compounds as PPARα and PPARγ activators
WO2000037081A1 (en) * 1998-12-22 2000-06-29 Novo Nordisk A/S Novel formulation
US6207682B1 (en) 1998-12-22 2001-03-27 Novo Nordisk A/S Modified release formulations containing (R)-1-(10,11-dihydro-5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1propyl)-3-piperidinecarboxylic acid
US7355042B2 (en) 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
US7541365B2 (en) * 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US20040087642A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
TWI291467B (en) * 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
US20070066570A1 (en) * 2003-06-16 2007-03-22 Michael Solomon Methods for treating sleep disorders
EP2061788A4 (en) * 2006-09-01 2010-10-06 Immune Control Inc NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH ACTIVATED LYMPHOCYTES
AR105911A1 (es) 2015-09-03 2017-11-22 Forma Therapeutics Inc Inhibidores de hdac8 bicíclicos fusionados [6,6]
EP3651751A4 (en) 2017-07-13 2021-03-31 Tonix Pharmaceuticals Holding Corp. CYCLOBENZAPRINE AND AMITRYPTILENE ANALOGUES
CN115850232B (zh) * 2023-02-16 2023-05-26 广州佳途科技股份有限公司 一种氟哌噻吨ep杂质h的制备方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3177211A (en) * 1957-07-26 1965-04-06 Sterling Drug Inc 10-[(aminocarbamyl-1-piperidyl)-loweralkyl]-phenothiazines

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3316249A (en) * 1967-04-25 Part a.xmethyl n n-(z-diethylaminoethyl)-n-(z- nitrophenyl) anthranilate hydrochloride
US2931810A (en) * 1960-04-05 Phenothiazine derivatives
BE552557A (https=) * 1955-11-15
NL108827C (https=) * 1956-04-09
NL99690C (https=) * 1956-11-15
NL222355A (https=) * 1957-11-05
FR1216268A (fr) * 1958-04-24 1960-04-25 Rhone Poulenc Sa Nouveaux dérivés de la phénothiazine à chaîne pipéridine substituée par une fonction amide et leur préparation
US3069432A (en) * 1961-02-20 1962-12-18 Olin Mathieson 5-(aminoalkyl)-5, 11-dihydrodibenzo-oxazepines
DE1159954B (de) * 1961-11-25 1963-12-27 Boehringer & Soehne Gmbh Verfahren zur Herstellung neuer 10-(Alkoxypiperidinopropyl)-phenthiazine und ihrer Salze
US3157658A (en) * 1963-07-05 1964-11-17 Searle & Co 1-carbalkoxy-4-(9-xanthenyl) piperazines and related compounds
BE664609A (https=) * 1964-06-01
US3886170A (en) * 1974-04-22 1975-05-27 Robins Co Inc A H 5-(3-)SUBSTITUTED-10,11-DIHYDRO-5H-dibenz{8 b,f{9 azepines
US4888335A (en) * 1988-07-25 1989-12-19 Mcneilab, Inc. 3-alkoxy-2-aminopropyl heterocyclic amines and their use as cardiovascular agents
US5296602A (en) * 1991-03-18 1994-03-22 Sloan-Kettering Institute For Cancer Research Multisubstituted 1-hydroxy-9-acridones with anticancer activity
US5420123A (en) * 1992-12-21 1995-05-30 Bristol-Myers Squibb Company Dibenzodiazepine endothelin antagonists
US5538986A (en) * 1993-12-06 1996-07-23 Schering Corporation Tricyclic derivatives, compositions and methods of use
MY113463A (en) * 1994-01-04 2002-03-30 Novo Nordisk As Novel heterocyclic compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3177211A (en) * 1957-07-26 1965-04-06 Sterling Drug Inc 10-[(aminocarbamyl-1-piperidyl)-loweralkyl]-phenothiazines

Also Published As

Publication number Publication date
DE69516394D1 (de) 2000-05-25
CA2180238A1 (en) 1995-07-13
SK88196A3 (en) 1997-06-04
US6043239A (en) 2000-03-28
JPH09507239A (ja) 1997-07-22
EP0738262B1 (en) 2000-04-19
US5668129A (en) 1997-09-16
PL180209B1 (pl) 2001-01-31
TW300887B (https=) 1997-03-21
AU1311095A (en) 1995-08-01
NO962811L (no) 1996-09-04
UA47396C2 (uk) 2002-07-15
US5595989A (en) 1997-01-21
BR9506452A (pt) 1997-09-02
PE45095A1 (es) 1995-12-18
NO306295B1 (no) 1999-10-18
NZ277763A (en) 2001-11-30
AU691858B2 (en) 1998-05-28
SG50602A1 (en) 1998-07-20
ES2147837T3 (es) 2000-10-01
ATE191909T1 (de) 2000-05-15
SI9520023A (en) 1997-04-30
IL112222A (en) 1999-12-31
PT738262E (pt) 2000-10-31
US5693649A (en) 1997-12-02
HUT75878A (en) 1997-05-28
US5721254A (en) 1998-02-24
NO962811D0 (no) 1996-07-03
DK0738262T3 (da) 2000-09-04
HU9601842D0 (en) 1996-09-30
CZ192196A3 (en) 1997-05-14
RU2167152C2 (ru) 2001-05-20
EP0738262A1 (en) 1996-10-23
US5688788A (en) 1997-11-18
JP2944221B2 (ja) 1999-08-30
IL112222A0 (en) 1995-03-30
GR3033967T3 (en) 2000-11-30
FI114025B (fi) 2004-07-30
CN1142226A (zh) 1997-02-05
US5712292A (en) 1998-01-27
US5795888A (en) 1998-08-18
FI962749L (fi) 1996-09-04
FI962749A0 (fi) 1996-07-04
BG100692A (en) 1997-09-30
WO1995018793A1 (en) 1995-07-13
KR100329450B1 (ko) 2002-10-04
DE69516394T2 (de) 2000-10-26
MY113463A (en) 2002-03-30
CZ286109B6 (cs) 2000-01-12

Similar Documents

Publication Publication Date Title
CN1083431C (zh) 新的杂环化合物
CN1273451C (zh) 哌啶mch拮抗剂及其治疗肥胖症的用途
CN1117569C (zh) 双环纤维蛋白原拮抗剂
CN1152030C (zh) 新的杂环化合物
CN1034072C (zh) 四氢咔唑衍生物的制备方法
CN1032209C (zh) 抗局部缺血剂2-呱啶子基-1-链烷醇衍生物的制备方法
CN1449382A (zh) 用作降脂质剂的多芳基羧酰胺类化合物
CN1047385C (zh) 3-吲哚基哌啶和含有它们的药物组合物
CN1202169A (zh) 作为5－ht4或h3受体配位体有效的5－苯基－3－(哌啶－4－基)－1,3,4－噁二唑－2(3h)－酮衍生物
CN1234797A (zh) N－取代的氮杂环化合物
CN1845921A (zh) 金刚烷和氮杂双环－辛烷及壬烷衍生物、其制备方法及其作为dpp－iv抑制剂的用途
CN1230432C (zh) 取代的苯基－哌嗪衍生物及其制备和用途
CN1067889A (zh) 取代的n-(1-烷基-3-羟基-4-哌啶基)苯甲酰胺的制备方法
CN1027368C (zh) 新型取代的喹啉衍生物的制备方法
CN1826115A (zh) 取代的哌啶化合物及其用法
CN1798744A (zh) 作为nmda/nr2b拮抗剂的3－氟－哌啶化合物
CN1046330A (zh) 四氢苯并[c，d]吲哚5-羟色胺兴奋剂
CN1897941A (zh) 趋化因子受体活性的烷基氨基、芳基氨基以及氨磺酰基环戊基酰胺调节剂
CN1890217A (zh) 作为载脂蛋白b抑制剂的n－芳基哌啶取代的联苯基甲酰胺
CN1041088C (zh) 光学活性咪唑烷酮衍生物和抗痴呆药物组合物
CN1311785A (zh) 作为甘氨酸拮抗剂的四氢喹啉衍生物
CN1037510C (zh) 制备吲哚衍生物的方法
CN1246312C (zh) 新的抗组胺哌啶衍生物及制备其的中间体
CN1134149A (zh) 苯基吲哚化合物
CN1043990C (zh) 咪唑啉酮衍生物、其酸的加成盐及老年痴呆症的治疗药物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee